SAGE-718: Will it be another failed CNS cognition asset?
According to the recent Cowen call, the street is not giving SAGE-718 asset much value because of the difficulties in prior clinical trials trying to show cognition improvements in diseases like Parkinson's and Alzheimer's. There is important Phase 2 data on the way some time this quarter or next. Will this be another failed CNS cognition program, or is this a hidden gem?
#SAGE $SAGE #SAGE-718 #CNS #parkinsons #alzheimers
9 Views